OCUP
Ocuphire Pharma, Inc. [OCUP] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
OCUP Stock Summary
Top 10 Correlated ETFs
OCUP
Top 10 Correlated Stocks
OCUP
In the News
OCUP Financial details
Company Rating
Neutral
Market Cap
45.66M
Income
-9.65M
Revenue
19.05M
Book val./share
2.17
Cash/share
2.2
Dividend
-
Dividend %
-
Employees
14
Optionable
No
Shortable
Yes
Earnings
13 May 2024
P/E
2.4
Forward P/E
-
PEG
-0.16
P/S
1.29
P/B
1.39
P/C
0.76
P/FCF
3.18
Quick Ratio
13.74
Current Ratio
13.86
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.45
EPS next Y
-
EPS next Q
-
EPS this Y
-151.11%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-85.83%
EPS Q/Q
-180.77%
-
-
-
-
SMA20
-
SMA50
-33.33%
SMA100
-33.33%
Inst Own
16.69%
Inst Trans
0.95%
ROA
54%
ROE
66%
ROC
0.58%
Gross Margin
100%
Oper. Margin
51%
Profit Margin
51%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.71-6.6
52W High
-72%
52W Low
+68%
RSI
34
Rel Volume
1.02
Avg Volume
221.83K
Volume
225.78K
Perf Week
-9.68%
Perf Month
-29.41%
Perf Quarter
-39.68%
Perf Half Y
-48.78%
-
-
-
-
Beta
0.242
-
-
Volatility
0.05%, 0.14%
Prev Close
-3.45%
Price
1.68
Change
-3.45%
OCUP Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0.04 | 2 | 0.88 | |
| Net income per share | -10.56 | -6.75 | -3.81 | 0.9 | -0.46 | |
| Operating cash flow per share | -5.05 | -1.46 | -1.3 | 0.72 | -0.05 | |
| Free cash flow per share | -5.09 | -1.77 | -1.31 | 0.72 | -0.05 | |
| Cash per share | 6.38 | 3.52 | 1.67 | 2.14 | 2.34 | |
| Book value per share | -10.63 | -2.89 | 1.5 | 2.32 | 2.31 | |
| Tangible book value per share | -10.63 | -2.89 | 1.5 | 2.32 | 2.31 | |
| Share holders equity per share | -10.63 | -2.89 | 1.5 | 2.32 | 2.31 | |
| Interest debt per share | 10.04 | 1.47 | 0.04 | 0 | 0 | |
| Market cap | 5.43M | 30.25M | 55.4M | 70.36M | 64.99M | |
| Enterprise value | 9.56M | 13.85M | 31.4M | 27.72M | 14.48M | |
| P/E ratio | -0.72 | -0.96 | -0.98 | 3.93 | -6.51 | |
| Price to sales ratio | 0 | 0 | 94.06 | 1.77 | 3.41 | |
| POCF ratio | -1.51 | -4.45 | -2.86 | 4.92 | -58.44 | |
| PFCF ratio | -1.5 | -3.66 | -2.85 | 4.92 | -58.44 | |
| P/B Ratio | -0.72 | -2.25 | 2.49 | 1.52 | 1.3 | |
| PTB ratio | -0.72 | -2.25 | 2.49 | 1.52 | 1.3 | |
| EV to sales | 0 | 0 | 53.32 | 0.7 | 0.76 | |
| Enterprise value over EBITDA | -2.25 | -1.47 | -1.37 | 1.52 | -1.37 | |
| EV to operating cash flow | -2.66 | -2.04 | -1.62 | 1.94 | -13.03 | |
| EV to free cash flow | -2.64 | -1.67 | -1.61 | 1.94 | -13.03 | |
| Earnings yield | -1.38 | -1.04 | -1.02 | 0.25 | -0.15 | |
| Free cash flow yield | -0.67 | -0.27 | -0.35 | 0.2 | -0.02 | |
| Debt to equity | -0.76 | 0 | 0.02 | 0 | 0 | |
| Debt to assets | 3.21 | 0 | 0.02 | 0 | 0 | |
| Net debt to EBITDA | -0.97 | 1.74 | 1.05 | -2.34 | 4.78 | |
| Current ratio | 0.19 | 5.55 | 6.76 | 17.79 | 13.35 | |
| Interest coverage | -2.98 | -2.92 | -11.35K | 2.03K | 0 | |
| Income quality | 0.58 | 0.28 | 0.34 | 0.8 | 0.11 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 13.79 | 0.18 | 0.63 | |
| Research and developement to revenue | 0 | 0 | 25.76 | 0.36 | 0.93 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.01 | 0.22 | 0.01 | 0 | 0 | |
| Capex to revenue | 0 | 0 | -0.17 | 0 | 0 | |
| Capex to depreciation | -8.33 | -184.38 | -25 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 3.25 | 0.05 | 0.18 | |
| Graham number | 50.25 | 20.95 | 11.32 | 6.84 | 4.9 | |
| ROIC | 3.14 | 1.9 | -0.99 | 0.39 | -0.21 | |
| Return on tangible assets | -4.21 | -1.78 | -2.17 | 0.37 | -0.19 | |
| Graham Net | -6.56 | -3.16 | 1.41 | 2.19 | 2.23 | |
| Working capital | -7.58M | 14.48M | 22.21M | 46.23M | 49.91M | |
| Tangible asset value | -7.56M | -13.47M | 22.22M | 46.24M | 49.91M | |
| Net current asset value | -7.58M | -13.48M | 22.21M | 46.23M | 49.91M | |
| Invested capital | -0.76 | 0 | 0.02 | 0 | 0 | |
| Average receivables | 62.5K | 62.5K | 0 | 2.43M | 3.59M | |
| Average payables | 171K | 778K | 1.4M | 1.33M | 1.61M | |
| Average inventory | 47.5K | 47.5K | 0 | 0.5 | 0.5 | |
| Days sales outstanding | 0 | 0 | 0 | 44.42 | 44.7 | |
| Days payables outstanding | 41.61K | 55.39K | 144.54K | 97.55K | 130.97K | |
| Days of inventory on hand | 11.56K | 0 | 0 | 0.09 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 8.22 | 8.17 | |
| Payables turnover | 0.01 | 0.01 | 0 | 0 | 0 | |
| Inventory turnover | 0.03 | 0 | 0 | 4K | 0 | |
| ROE | 0.99 | 2.34 | -2.54 | 0.39 | -0.2 | |
| Capex per share | -0.04 | -0.32 | -0.01 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 1.92 | 0.08 | 0.18 | 0.56 | 0.07 | |
| Net income per share | 1.63 | -0.26 | -0.24 | 0.26 | -0.21 | |
| Operating cash flow per share | 1.38 | -0.17 | 0.05 | -0.14 | 0.2 | |
| Free cash flow per share | 1.38 | -0.17 | 0.05 | -0.14 | 0.2 | |
| Cash per share | 2.05 | 1.86 | 1.91 | 1.98 | 2.2 | |
| Book value per share | 2.22 | 1.97 | 1.8 | 2.34 | 2.17 | |
| Tangible book value per share | 2.22 | 1.97 | 1.8 | 2.34 | 2.17 | |
| Share holders equity per share | 2.22 | 1.97 | 1.8 | 2.34 | 2.17 | |
| Interest debt per share | 0 | -0.02 | 0 | 0 | 0 | |
| Market cap | 73.45M | 78.52M | 90.97M | 71.85M | 69.21M | |
| Enterprise value | 30.82M | 39.54M | 50.99M | 29.5M | 18.71M | |
| P/E ratio | 0.54 | -3.6 | -4.58 | 3.23 | -3.61 | |
| Price to sales ratio | 1.84 | 44.9 | 24.76 | 6.02 | 40.93 | |
| POCF ratio | 2.55 | -21.54 | 91.98 | -23.92 | 15.22 | |
| PFCF ratio | 2.55 | -21.54 | 91.98 | -23.92 | 15.22 | |
| P/B Ratio | 1.59 | 1.9 | 2.41 | 1.43 | 1.39 | |
| PTB ratio | 1.59 | 1.9 | 2.41 | 1.43 | 1.39 | |
| EV to sales | 0.77 | 22.6 | 13.88 | 2.47 | 11.06 | |
| Enterprise value over EBITDA | 0.9 | -6.83 | -10.28 | 4.62 | -3.45 | |
| EV to operating cash flow | 1.07 | -10.84 | 51.56 | -9.82 | 4.11 | |
| EV to free cash flow | 1.07 | -10.84 | 51.56 | -9.82 | 4.11 | |
| Earnings yield | 0.46 | -0.07 | -0.05 | 0.08 | -0.07 | |
| Free cash flow yield | 0.39 | -0.05 | 0.01 | -0.04 | 0.07 | |
| Debt to equity | 0 | 0 | 0 | 0 | 0 | |
| Debt to assets | 0 | 0 | 0 | 0 | 0 | |
| Net debt to EBITDA | -1.24 | 6.73 | 8.06 | -6.63 | 9.31 | |
| Current ratio | 17.79 | 10.93 | 7.54 | 13.86 | 13.35 | |
| Interest coverage | 3.8K | 18.03 | 0 | 0 | 0 | |
| Income quality | 0.85 | 0.63 | -0.2 | -0.54 | -0.95 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.05 | 1.31 | 1.18 | 0.17 | 0 | |
| Research and developement to revenue | 0.09 | 3.2 | 1.29 | 0.29 | 2.27 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0.01 | 0.46 | 0.39 | 0.05 | 0.42 | |
| Graham number | 9.03 | 3.4 | 3.1 | 3.7 | 3.19 | |
| ROIC | 0.73 | -0.14 | -0.16 | 0.13 | -0.11 | |
| Return on tangible assets | 0.69 | -0.12 | -0.11 | 0.1 | -0.09 | |
| Graham Net | 2.09 | 1.85 | 1.75 | 2.2 | 2.1 | |
| Working capital | 46.23M | 41.25M | 37.7M | 50.28M | 49.91M | |
| Tangible asset value | 46.24M | 41.25M | 37.7M | 50.28M | 49.91M | |
| Net current asset value | 46.23M | 41.25M | 37.7M | 50.28M | 49.91M | |
| Invested capital | 0 | 0 | 0 | 0 | 0 | |
| Average receivables | 2.43M | 5.08M | 4.02M | 7.04M | 6.84M | |
| Average payables | 1.27M | 1.65M | 2.27M | 2.11M | 2.02M | |
| Average inventory | 0.5 | 0.5 | 343.5K | 560K | 216.5K | |
| Days sales outstanding | 10.95 | 272.78 | 66.88 | 85.54 | 124.17 | |
| Days payables outstanding | 96.21K | 199.89K | 209.07K | 170.1K | 64.59K | |
| Days of inventory on hand | 0.09 | 0 | 61.83K | 38.97K | 0 | |
| Receivables turnover | 8.22 | 0.33 | 1.35 | 1.05 | 0.72 | |
| Payables turnover | 0 | 0 | 0 | 0 | 0 | |
| Inventory turnover | 1000 | 0 | 0 | 0 | 0 | |
| ROE | 0.73 | -0.13 | -0.13 | 0.11 | -0.1 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
OCUP Frequently Asked Questions
What is Ocuphire Pharma, Inc. stock symbol ?
Ocuphire Pharma, Inc. is a US stock , located in Farmington hills of Mi and trading under the symbol OCUP
What is Ocuphire Pharma, Inc. stock quote today ?
Ocuphire Pharma, Inc. stock price is $1.68 today.
Is Ocuphire Pharma, Inc. stock public?
Yes, Ocuphire Pharma, Inc. is a publicly traded company.
Company Profile
- Volume Average 221.83K
- Market Capitalization 45.66M
- Employee 14
- CEO Mr. George Magrath M.B.A., M.D., M.S.
- Headquarters Farmington Hills,MI,US
- IPO Date 2005-11-10
-
Website
https://www.ocuphire.com 
Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate, which is in Phase III clinical trial for dim light or night vision disturbances; and Phase 2b clinical trial for pharmacologically induced mydriasis, as well as that has completed Phase 2 VEGA-1 trial for presbyopia. The company also develops APX3330, a twice-a-day oral tablet to target pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy and diabetic macular edema; and APX2009 and APX2014 second generation preclinical product candidates and analogs of APX3330. Ocuphire Pharma, Inc. is headquartered in Farmington Hills, Michigan.
